See more : Abacus Life, Inc. (ABLLW) Income Statement Analysis – Financial Results
Complete financial analysis of Evotec SE (EVO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evotec SE, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- AR advanced technology, Inc. (5578.T) Income Statement Analysis – Financial Results
- Joey New York, Inc. (JOEY) Income Statement Analysis – Financial Results
- Nature’s Sunshine Products, Inc. (NATR) Income Statement Analysis – Financial Results
- Hancock Whitney Corporation (HWC) Income Statement Analysis – Financial Results
- Purshottam Investofin Limited (PURSHOTTAM.BO) Income Statement Analysis – Financial Results
Evotec SE (EVO)
About Evotec SE
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 781.43M | 751.45M | 618.03M | 500.92M | 446.44M | 375.41M | 257.63M | 164.51M | 127.68M | 89.50M | 85.94M | 87.27M | 80.13M | 55.26M | 42.68M | 39.61M | 32.89M | 67.35M | 64.12M | 1.94M | 3.57M | 0.00 | 0.00 |
| Cost of Revenue | 606.38M | 577.38M | 466.49M | 375.18M | 313.55M | 263.39M | 175.06M | 105.95M | 89.69M | 60.12M | 54.72M | 56.24M | 45.14M | 30.92M | 24.26M | 21.98M | 24.86M | 44.40M | 42.99M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 175.05M | 174.07M | 151.54M | 125.74M | 132.89M | 112.02M | 82.57M | 58.55M | 37.99M | 29.38M | 31.22M | 31.02M | 34.99M | 24.35M | 18.42M | 17.64M | 8.02M | 22.95M | 21.13M | 1.94M | 3.57M | 0.00 | 0.00 |
| Gross Profit Ratio | 22.40% | 23.16% | 24.52% | 25.10% | 29.77% | 29.84% | 32.05% | 35.59% | 29.75% | 32.83% | 36.33% | 35.55% | 43.66% | 44.06% | 43.16% | 44.52% | 24.40% | 34.08% | 32.95% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 57.52M | 76.64M | 72.20M | 63.95M | 58.43M | 35.62M | 17.61M | 18.11M | 18.34M | 12.40M | 9.66M | 8.34M | 8.44M | 6.12M | 20.95M | 42.54M | 36.94M | 30.31M | 9.30M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 152.74M | 142.70M | 96.02M | 77.24M | 66.55M | 57.01M | 42.38M | 27.01M | 25.17M | 17.99M | 16.60M | 16.30M | 15.76M | 15.96M | 16.70M | 19.95M | 17.81M | 18.58M | 15.54M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 16.87M | 13.49M | 9.42M | 9.50M | 9.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 169.61M | 156.19M | 105.45M | 77.24M | 66.55M | 57.01M | 42.38M | 27.01M | 25.17M | 17.99M | 16.60M | 16.30M | 15.76M | 15.96M | 16.70M | 19.95M | 17.81M | 18.58M | 15.54M | 6.10M | 5.27M | 5.02M | 4.27M |
| Other Expenses | -4.57M | -79.62M | -67.78M | -67.21M | -66.60M | 257.00K | -209.00K | 4.00K | 263.00K | 39.00K | 16.00K | 171.00K | 1.49M | 1.80M | -3.29M | -11.87M | 149.00K | 274.00K | 614.00K | -38.30M | -41.99M | -28.93M | -17.01M |
| Operating Expenses | 222.56M | 153.22M | 109.86M | 73.98M | 58.38M | 49.22M | 43.89M | 21.81M | 40.52M | 27.24M | 27.05M | 30.72M | 30.65M | 27.17M | 38.03M | 63.13M | 57.24M | 53.75M | 36.26M | -32.20M | -36.72M | -23.91M | -12.74M |
| Cost & Expenses | 828.93M | 730.60M | 576.36M | 449.16M | 371.92M | 312.61M | 218.96M | 127.76M | 130.21M | 87.35M | 81.77M | 86.96M | 75.79M | 58.08M | 62.30M | 85.11M | 82.10M | 98.15M | 79.25M | -32.20M | -36.72M | -23.91M | -12.74M |
| Interest Income | 9.26M | 8.34M | 2.27M | 1.34M | 2.23M | 898.00K | 903.00K | 863.00K | 533.00K | 469.00K | 261.00K | 655.00K | 413.00K | 241.00K | 499.00K | 2.96M | 1.96M | 1.37M | 851.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 11.74M | 13.15M | 9.25M | 8.47M | 7.46M | 2.59M | 1.26M | 1.52M | 1.73M | 1.62M | 1.87M | 1.86M | 1.86M | 866.00K | 433.00K | 839.00K | 483.00K | 671.00K | 698.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 92.98M | 81.66M | 67.61M | 56.06M | 48.81M | 31.29M | 20.77M | 11.89M | 11.94M | 8.54M | 9.17M | 8.82M | 6.61M | 5.51M | 4.78M | 5.13M | 8.94M | 9.61M | 16.40M | 2.14M | 2.03M | 0.00 | 0.00 |
| EBITDA | 24.13M | -86.08M | 298.41M | 75.50M | 86.77M | 105.88M | 35.50M | 45.57M | 24.93M | 5.00M | -14.07M | 4.51M | 13.90M | 9.49M | -39.61M | -70.01M | -36.08M | -22.15M | -18.44M | -67.56M | -31.12M | -23.91M | -12.74M |
| EBITDA Ratio | 3.09% | 12.53% | 15.36% | 19.76% | 27.25% | 25.25% | 22.65% | 29.87% | 7.99% | 12.50% | 15.84% | 11.40% | 17.82% | 16.76% | -40.03% | -125.03% | -109.71% | -29.29% | -0.94% | -1,452.23% | -870.96% | 0.00% | 0.00% |
| Operating Income | -47.51M | 12.50M | 27.32M | 48.52M | 62.59M | 77.46M | 37.50M | 31.34M | 11.64M | -6.38M | -21.35M | -3.20M | 5.21M | 1.72M | -42.30M | -73.21M | -58.12M | -36.76M | -32.97M | -30.26M | -33.15M | -23.91M | -12.74M |
| Operating Income Ratio | -6.08% | 1.66% | 4.42% | 9.69% | 14.02% | 20.63% | 14.55% | 19.05% | 9.12% | -7.13% | -24.84% | -3.67% | 6.50% | 3.10% | -99.10% | -184.81% | -176.72% | -54.58% | -51.42% | -1,562.82% | -927.80% | 0.00% | 0.00% |
| Total Other Income/Expenses | -33.09M | -174.81M | 195.98M | -22.72M | -6.03M | -5.46M | -11.16M | 1.61M | 851.00K | 1.22M | -2.30M | -6.55M | 49.00K | 2.15M | -21.16M | -28.20M | 1.37M | -1.46M | -20.40M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -80.59M | -153.96M | 236.98M | 25.81M | 56.56M | 72.00M | 26.33M | 32.95M | 12.49M | -5.16M | -23.65M | -5.01M | 5.26M | 3.87M | -44.82M | -75.97M | -54.41M | -35.98M | -35.53M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -10.31% | -20.49% | 38.34% | 5.15% | 12.67% | 19.18% | 10.22% | 20.03% | 9.78% | -5.76% | -27.52% | -5.75% | 6.56% | 7.00% | -105.00% | -191.78% | -165.44% | -53.41% | -55.42% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.32M | 21.70M | 21.47M | 19.56M | 19.33M | -12.06M | 2.33M | 6.11M | -4.03M | 1.82M | 1.79M | -7.49M | -1.40M | 882.00K | 678.00K | 2.32M | -6.35M | 320.00K | -4.53M | -798.91K | 96.08K | 23.90M | 12.77M |
| Net Income | -83.91M | -175.66M | 215.51M | 6.28M | 38.16M | 84.17M | 24.26M | 27.53M | 16.52M | -6.98M | -25.43M | 2.48M | 6.75M | 3.26M | -45.50M | -78.29M | -11.16M | -32.47M | -33.58M | -29.46M | -33.25M | -23.90M | -12.77M |
| Net Income Ratio | -10.74% | -23.38% | 34.87% | 1.25% | 8.55% | 22.42% | 9.42% | 16.73% | 12.94% | -7.80% | -29.59% | 2.84% | 8.42% | 5.90% | -106.59% | -197.63% | -33.92% | -48.21% | -52.38% | -1,521.56% | -930.49% | 0.00% | 0.00% |
| EPS | -0.47 | -0.99 | 1.30 | 0.04 | 0.25 | 0.57 | 0.16 | 0.20 | 0.13 | -0.05 | -0.21 | 0.02 | 0.06 | 0.03 | -0.43 | -0.82 | -0.16 | -0.49 | -0.65 | -1.36 | -37.01 | -39.97 | -40.78 |
| EPS Diluted | -0.47 | -0.99 | 1.30 | 0.04 | 0.25 | 0.57 | 0.16 | 0.20 | 0.12 | -0.05 | -0.21 | 0.02 | 0.06 | 0.03 | -0.43 | -0.82 | -0.16 | -0.49 | -0.65 | -1.36 | -37.01 | -39.97 | -40.78 |
| Weighted Avg Shares Out | 176.92M | 176.67M | 166.41M | 153.75M | 149.73M | 147.48M | 145.01M | 132.51M | 131.68M | 131.29M | 121.22M | 117.30M | 116.02M | 109.01M | 106.85M | 95.20M | 71.83M | 66.36M | 51.99M | 21.71M | 898.27K | 597.93K | 313.09K |
| Weighted Avg Shares Out (Dil) | 176.92M | 176.70M | 166.41M | 153.75M | 149.73M | 147.48M | 145.01M | 132.51M | 137.63M | 131.29M | 121.22M | 117.30M | 116.02M | 109.01M | 106.85M | 95.20M | 71.83M | 66.36M | 51.99M | 21.71M | 898.27K | 597.93K | 313.09K |
Evotec And Claris Ventures Streamline Access to Accelerate Programmes from Claris's Portfolio Companies into The Clinic
CLARIS'S PORTFOLIO COMPANIES RECEIVE EASY ACCESS TO EVOTEC'S FULL RANGE OF PRE-CLINICAL AND CLINICAL DEVELOPMENT AND MANUFACTURING CAPABILITIES AGREEMENT BUILDS ON SUCCESSFUL COLLABORATION BETWEEN EVOTEC AND CLARIS'S PORTFOLIO COMPANY IAMA HAMBURG, GERMANY / TURIN, ITALY / ACCESSWIRE / March 6,...
7 Stable Stocks to Buy for 100% Returns by 2025
The seven stable stocks discussed below each have the potential to double by 2025 based on analyst target prices. Each of the seven stocks is also relatively stable based on the fact that none have a beta higher than 1.4.
Just - Evotec Biologics Expands Development and Manufacturing Agreement with ABL for Broadly Neutralising Antibodies Against HIV
JUST - EVOTEC BIOLOGICS TO PROVIDE DEVELOPMENT AND PHASE I CLINICAL MANUFACTURING OF BROADLY NEUTRALISING ANTIBODY AGAINST HIV AGREEMENT BUILDS ON PREVIOUS NIAID-FUNDED COLLABORATION TO DEVELOP A BROADLY NEUTRALISING ANTIBODY AGAINST HIV HAMBURG, GERMANY / ACCESSWIRE / February 7, 2024...
Evotec SE (EVO) Business Update Conference Call (Transcript)
Evotec SE (EVO) Business Update Conference Call (Transcript)
Evotec says it promptly reported share trades of former CEO
German biotech firm Evotec on Monday said it had immediately reported trades in its shares by its former CEO over three years, as soon as it was belatedly informed of the transactions in the wake of the executive's recent departure.
Evotec SE: Invitation to Conference Call
HAMBURG, GERMANY / ACCESSWIRE / January 22, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) is going to hold a conference call to provide a statement as well as a business update on Monday, 22 January 2024....
Evotec and Crohn's & Colitis Foundation Enter Agreement to Advance Drug Discovery for Novel IBD Therapies
EVOTEC JOINS FORCES WITH THE CROHN'S & COLITIS FOUNDATION'S IBD THERAPEUTICS INCUBATOR TO ADVANCE DRUG DISCOVERY AND IDENTIFY NOVEL THERAPIES FOR INFLAMMATORY BOWEL DISEASE ("IBD") THE COLLABORATION LEVERAGES EVOTEC'S END-TO-END INTEGRATED R&D PLATFORM TO ADVANCE DRUG DISCOVERY FOR TWO INNOVATIVE...
Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb
KEY SCIENTIFIC ACHIEVEMENT ADVANCES THE JOINT NEUROSCIENCE PIPELINE AND EARNS A PAYMENT OF US$ 25 M TO EVOTEC TO PROGRESS FURTHER RESEARCH HAMBURG, GERMANY / ACCESSWIRE / January 8, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809;...
Why Is Evotec (EVO) Stock Down 12% Today?
Evotec (NASDAQ: EVO ) stock is falling on Thursday after the drug discovery and development partner announced the resignation of CEO Dr. Werner Lanthaler. According to a press release from the company, Lanthaler departure is immediate and won't see him finish...
Evotec and Owkin Enter an A.I.-Powered Strategic Partnership to Accelerate Therapeutics Pipeline in Oncology and I&I
PARTNERSHIP COMBINES OWKIN'S A.I. TARGET DISCOVERY CAPABILITIES WITH EVOTEC'S INTEGRATED END-TO-END SHARED R&D PLATFORM A.I.
Source: https://incomestatements.info
Category: Stock Reports